Icatibant Teva (Icatibant Acetate)

Icatibant acetate works by selectively and competitively antagonizing the bradykinin B2 receptor on vascular endothelial cells. This blocks bradykinin‑mediated signaling that leads to vasodilation and increased vascular permeability, thereby preventing the swelling characteristic of hereditary angioedema.

The dose of Icatibant Teva is determined by the prescribing clinician based on the patient’s condition and clinical response. Typically, a single subcutaneous injection of 30 mg is administered at the onset of an HAE attack, but the exact regimen should follow the prescriber’s instructions.

Safety data for Icatibant Teva in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Icatibant Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

The primary alternative for acute HAE attacks is C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant directly blocks bradykinin receptors, offering a rapid, subcutaneous option that does not require plasma‑derived products. Choice of therapy depends on patient preference, availability, and specific clinical considerations.

Icatibant Teva must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If temporary temperature excursions occur, the product should be inspected for any changes before use.

Icatibant Teva is administered as a single subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction. No infusion set or IV access is required.

Serious risks include hypersensitivity reactions such as rash, urticaria, or anaphylaxis, and rare cases of severe abdominal pain or thrombocytopenia. Patients should be monitored for any signs of allergic response or unexpected systemic symptoms after injection and seek immediate medical attention if they occur.

Icatibant Teva should be avoided in individuals with known hypersensitivity to icatibant acetate or any of the formulation excipients. Caution is also advised for patients with a history of severe allergic reactions, and it is not recommended for use in pregnancy or breastfeeding unless clearly justified by a physician.